KR20070063112A - Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method - Google Patents
Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method Download PDFInfo
- Publication number
- KR20070063112A KR20070063112A KR1020050123015A KR20050123015A KR20070063112A KR 20070063112 A KR20070063112 A KR 20070063112A KR 1020050123015 A KR1020050123015 A KR 1020050123015A KR 20050123015 A KR20050123015 A KR 20050123015A KR 20070063112 A KR20070063112 A KR 20070063112A
- Authority
- KR
- South Korea
- Prior art keywords
- seaweed
- bile
- fraction
- adsorption capacity
- sulfated polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001282 polysaccharide Polymers 0.000 title claims description 25
- 239000005017 polysaccharide Substances 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000001179 sorption measurement Methods 0.000 title description 23
- 210000000941 bile Anatomy 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 239000003833 bile salt Substances 0.000 claims abstract description 22
- 229940093761 bile salts Drugs 0.000 claims abstract description 16
- 150000004804 polysaccharides Chemical class 0.000 claims description 23
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 11
- 239000000783 alginic acid Substances 0.000 claims description 9
- 229960001126 alginic acid Drugs 0.000 claims description 9
- 150000004781 alginic acids Chemical class 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 241000199919 Phaeophyceae Species 0.000 claims 2
- 239000007857 degradation product Substances 0.000 claims 2
- 241001474374 Blennius Species 0.000 abstract description 29
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 239000003613 bile acid Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 230000006862 enzymatic digestion Effects 0.000 description 8
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940009976 deoxycholate Drugs 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229920001268 Cholestyramine Polymers 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001261506 Undaria pinnatifida Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940009025 chenodeoxycholate Drugs 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- -1 steroid compound Chemical class 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- AUTALUGDOGWPQH-UBLOVXTBSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(2r,3s,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O AUTALUGDOGWPQH-UBLOVXTBSA-N 0.000 description 1
- IMIVWAUMTAIVPJ-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-azaniumyl-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-methylpentanoate Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC(C)C IMIVWAUMTAIVPJ-XUXIUFHCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 241001261505 Undaria Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-AIHAYLRMSA-N alpha-D-ribose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-AIHAYLRMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical group [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical class [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
- C07H5/10—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium to sulfur
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
본 발명은 미역을 효소로 가수분해하여 획득한 가수분해물로부터 2차 담즙산염을 흡착하는 획분에 관한 것이다.The present invention relates to a fraction for adsorbing secondary bile salts from a hydrolyzate obtained by hydrolyzing seaweed with an enzyme.
Description
도 1은 1차담즙산염인 Na-cholate와 USF-1, USF-2의 140분간 흡착반응을 나타낸 것이다.Figure 1 shows the adsorption reaction of primary bile salts Na-cholate and USF-1, USF-2 for 140 minutes.
도 2는 1차담즙산염인 Na-chenodeoxycholate와 USF-1, USF-2의 140분간 흡착반응을 나타낸 것이다.Figure 2 shows the adsorption reaction of primary bile salts Na-chenodeoxycholate and USF-1, USF-2 for 140 minutes.
도 3은 2차담즙산염인 Na-deoxycholate와 USF-1, USF-2의 140분간 흡착반응을 나타낸 것이다.Figure 3 shows the adsorption reaction of secondary bile salts Na-deoxycholate and USF-1, USF-2 for 140 minutes.
도 4는 2차담즙산염인 Na-deoxycholate와 USF-1, USF-2, Cholestyramime의 140분간 흡착반응을 나타낸 것이다.Figure 4 shows the adsorption reaction of secondary bile salts Na-deoxycholate and USF-1, USF-2, Cholestyramime for 140 minutes.
한류와 난류가 교류하는 우리나라 연안의 해조 자원은 풍부하다. 생육하고 있는 해조류의 종류는 87과 241속 218종이며 이중 갈조류가 25과 57속 135종으로 알려져 있다. 이들 해조류는 예로부터 식용, 호로, 약용, 해조 공업의 원료, 가축사료 및 비료 등으로 이용되고 있으며, 그 종류는 약 60~70여 종으로 이들 해조류는 영양 생리효과가 뛰어난 것으로 밝혀지고 있다. There is abundant seaweed resources along the coast of Korea, where the Korean and turbulent flows. There are 218 species of genus 87, 241 genus, and 150 species of genus algae of 25 type, 57 genus 57. These seaweeds have been used for food, fenugreek, medicinal, raw materials of the seaweed industry, livestock feed and fertilizers since ancient times. About 60 to 70 kinds of these seaweeds have been found to have excellent nutritional physiological effects.
그 중 생산량이 가장 많은 것이 미역이며, 예로부터 산후조리 식품으로 애용되고 있다. 1970년 초반 양식업의 발달로 그 생산량이 급격히 증가하여 최근에 이르러 그 가공률이 10% 미만에 달하여 폐기량이 늘어가고 있다. Among them, the highest yield is seaweed, and has been used as a postpartum cooked food since ancient times. The development of aquaculture in the early 1970s led to a sharp increase in its production, and in recent years its disposal rate has fallen to less than 10%, leading to an increase in waste.
이는 미역의 수확시기기 2~4월의 3개월에 국한되어 마른미역, 염장미역 등 1차 가공 산품으로 주로 생산되기 때문이며 따라서 양식어민의 소득이 점차 줄어들고 중국의 수출증대로 인하여 수출시장에서의 점유율도 하락하고 있는 실정이다.This is because it is limited to 3 months of harvest season in February ~ April, and is mainly produced as a primary processed product such as dried seaweed and salted seaweed. It is also falling.
미역에 대한 연구로는 식이섬유로서 이용에 관한 연구, 발암성 니트로사민생성인자의 분해작용에 관한 연구 등 극히 제한된 보고가 있을 뿐이다. 이러한 저이용 미역의 잠재자원을 활용하여 가공원료로서의 가치를 높이고 효과적인 활용방안을 모색하는 것은 어민소득증대 뿐만 아니라 식량자원의 확보와 국민의 영양증진에 크게 기여할 것으로 기대된다.There are only a few reports on the use of seaweed as a dietary fiber, the study of carcinogenic nitrosamine production. The use of these low-use seaweed potential resources to increase the value as processed raw materials and to find effective ways to utilize them is expected to greatly contribute to securing food resources and improving the nutrition of the people, as well as increasing fishermen's income.
본 연구에서는 미역을 이용한 새로운 가공기술인 효소분해기법을 통하여 황산화다당을 크로마토그래피 기술로 분리하고자 하였다. In this study, we attempted to separate sulfated polysaccharide by chromatography using enzymatic digestion, a new processing technique using seaweed.
최근 한국인의 식생활문화의 서구화로 인해 과다한 지방섭취로 고콜레스테롤증의 잠재인구가 20%에 달한다는 보고가 있다. 한국인의 콜레스테롤 농도는 서양인의 콜레스테롤 수치에 비하여 아직 낮은 범위이지만 최근 10mg/dl이상 상승하였으 며, 저 연령층에서의 상승이 뚜렷이 나타나고 있다. 따라서 최근 수년간 고혈압, 동맥경화, 심장질환 환자 수가 급격히 증가하고 있으며, 심장질환 환자의 연령도 낮아지고 있는 추세이다. Recently, due to the westernization of Koreans' dietary culture, excessive fat intake has been reported that the potential population of hypercholesterolemia reaches 20%. The cholesterol level in Koreans is still lower than that of Westerners, but has recently risen above 10 mg / dl. Therefore, in recent years, the number of hypertension, arteriosclerosis, and heart disease patients is increasing rapidly, and the age of heart disease patients is decreasing.
콜레스테롤은 탄소수 27개로 이뤄진 불용성 스테로이드계 화합물로서, 프로게스틴, 코르티코스테로이드, 성호르몬등의 전구체로 작용하며, 소장으로부터 지방이나 지용성 비타민의 흡수에 필요한 담즙산을 형성, 간으로 부터 조직으로 운반하기 위해 간에서 형성되는 초저밀도 단백질(VLDL)합성에도 사용된다.Cholesterol is an insoluble steroid compound with 27 carbon atoms, which acts as a precursor to progestins, corticosteroids, and sex hormones, and forms bile acids necessary for the absorption of fat or fat-soluble vitamins from the small intestine and is carried by the liver to tissues from the liver. It is also used for the synthesis of ultra low density proteins (VLDL) that are formed.
콜레스테롤을 과다섭취하게 되면 혈관 내 축적하여 심장계 질환을 유발하는 것으로 알려져 있다. 아직까지는 저콜레스테롤 식이요법 외에는 예방할 방법이 없으며, 콜레스테롤 저하제 등으로 약품복용이 효과가 있으나 콜레스테롤 합성효소의 작용억제에 따른 간기능 장애 등의 부작용을 유발하는 등의 이유로 사용이 극히 제한적이다.Too much cholesterol is known to accumulate in blood vessels and cause heart disease. There is no preventive method yet except low cholesterol diet, and drug use is effective as a cholesterol lowering agent, but its use is extremely limited because it causes side effects such as liver dysfunction due to inhibition of cholesterol synthase.
콜레스테롤의 과다섭취로 인한 병변 발생율을 억제하기 위해 cholestyranmine, cholestipol 등이 사용되고 있으나 상기와 같은 간에 대한 복용상의 문제점이 있는 것으로 알려져 있다. 이들은 소장내 담즙산과 상호작용을 발휘하여 콜레스테롤의 재합성과 담즙산의 배출에 기여한다고 보고되고 있다. Although cholestyranmine, cholestipol, etc. are used to suppress the incidence of lesions caused by excessive intake of cholesterol, it is known that there are problems in taking the liver as described above. They have been reported to interact with bile acids in the small intestine, contributing to the resynthesis of cholesterol and the release of bile acids.
담즙산은 콜레스테롤이 간에서 산화됨으로써 생성되고, 장내로 분비되는데, 이들은 지질이나 지용성 비타민을 유화시키고, 회장부근에서 흡수되어 간으로 순환하는 장간 순환과정을 거치면서 일부(약 1%)만 배설되는 경로를 가지고 있다. 이때 흡착제를 사용하여, 회장부근에서 답즙산의 흡수를 막아, 체내 콜레스테롤의 소비 를 촉진 시키고, 또한 feed back 효과에 의해 장점막에서 생성된 콜레스테롤의 흡수를 차단, 배설하므로써 혈중 콜레스테롤을 값을 낮추는 방법이 사용된다. 이와 같은 방법은 1953년 siperstein 등이 수탉에 대해 ferric chloride를 사용하여 실험한 후, 이 원리를 이용하여 1960년에 Tennent 등이 cholestyramine(syrene과 divinylbezene의 공중합체)를 제조하여 동물실험을 거쳐 현재 상용되고 있다.Bile acids are produced by the oxidation of cholesterol in the liver and secreted into the intestines, which emulsify lipids or fat-soluble vitamins, and excrete only a portion (about 1%) during the intestinal cycle, which is absorbed in the ileum and circulated to the liver. Have At this time, the use of an adsorbent prevents the absorption of bile acids near the ileum, promotes the consumption of cholesterol in the body, and lowers the value of blood cholesterol by blocking and excreting the absorption of cholesterol produced in the urinary tract by the feed back effect. Used. This method was tested by ferric chloride on a rooster by siperstein in 1953, and then, by 1960, Tennent et al. Prepared cholestyramine (a copolymer of syrene and divinylbezene) using animal experiments. It is becoming.
담즙산은 염의 형태로, 생체 내에서 음이온으로 존재하게 된다. 이들 담즙산염은 1차 담즙산 염인 cholate, chenodeoxycholate 등이 있으며, 이들 1차 담즙산염이 장관내 미생물의 분해에 의해 2차 담즙산염인 decyholate 가 생성된다. Bile acids are present in the form of salts as anions in vivo. These bile salts include primary bile salts, cholate and chenodeoxycholate, and these primary bile salts produce decyholate as a secondary bile salt by the degradation of intestinal microorganisms.
본 발명은 국내 대규모 자원인 미역을 이용하여 효소분해기술로 그 수율을 증대 시켜 황산화다당을 추출하여 담즙산염의 흡착능을 시험하여 2차 담즘산염의 흡착능이 뛰어난 황산화다당 획분에 관한 것이다.The present invention relates to a sulfated polysaccharide having excellent adsorptive capacity of secondary bismuth salts by increasing the yield by enzymatic digestion technology using a large-scale domestic seaweed and extracting polysulfated polysaccharide to test the adsorption capacity of bile salts.
본 발명의 목적은 미역을 효소분해 시켜 그 추출수율을 증대 시키고, 그 중 황산화 다당을 추출하여 분자량 별로 획분한 다음 담즙산염 흡착이 뛰어난 황산화올리고당을 제공하는 것에 있다. An object of the present invention is to provide a sulfated oligosaccharide excellent in enzymatic digestion of wakame seaweed to increase its extraction yield, the sulfated polysaccharide is extracted by molecular weight and then bile salt adsorption.
상기의 목적을 달성하기 위하여, 본 발명은 미역을 다당류 분해효소로 분해하여 추출수율을 증대 시킨다. 열수추출이나 용매추출등에서는 동량으로 정제수를 투입하여 추출하더라도 추출수율이 5%미만이고 목적성분인 다당의 유출이 용이하지 않기 때문에 특별히 다당분해효소를 사용하여 추출한다. 추출 후 음이온 교환수지와 겔크로마토그래피를 통하여 황산화 다당을 추출하여 분자량 별로 답즙산 흡착능을 시험하여 활성분획을 분리한다.In order to achieve the above object, the present invention increases the extraction yield by decomposing the seaweed with polysaccharide degrading enzyme. In hot water extraction or solvent extraction, even if purified water is added in the same amount, the extraction yield is less than 5% and the extraction of polysaccharide as a target component is not easy, so it is extracted using polysaccharide enzyme. After extraction, the sulfated polysaccharides are extracted through anion exchange resin and gel chromatography, and the active fractions are separated by testing bile acid adsorption capacity by molecular weight.
실시 예 1. 미역의 효소분해Example 1 Enzymatic Degradation of Seaweed
먼저 미역의 이물질 등을 선별한 다음 수분함량이 7-10% 가 되게 열풍건조 한 후 길이로써 10cm 정도 크기로 절단한다. 미세 분말로 할 경우 발효기 내에서 수분의 함수율이 시료 건중량의 20배이상의 정제수를 투입하여야 교반가능하게 되므로 분말로 하기보다 절단하여 사용한다. First, the foreign matters of wakame seaweed are sorted and then hot air dried to 7-10% of moisture, and then cut to 10cm in length. In the case of fine powder, the water content of the fermenter is 20 times more than the dry weight of the sample.
절단된 미역 시료 200kg에 10배의 정제수를 투입하여 15분간 침지하여 수세한 후 액을 배출한다. 과하게 수세 할 경우 식이섬유 및 식이섬유와 에스테르 결합을 이루고 있는 황산기이 유출이 심하므로 침지하여 배출한다.10 times purified water is added to 200kg of cut seaweed samples, soaked for 15 minutes, washed, and then drained. In case of excessive washing, sulfuric acid group forming ester bond with dietary fiber and dietary fiber is seriously spilled and discharged by dipping.
수세와 1차 탈염된 미역 시료를 5톤 발효탱크에 투입하고, 투입 전 미리 80도씨로 가온된 정제수(시료의 15배 중량 W/W) 3톤에 Citrate-Phoshate buffer( 혼합비 Citrate 1: Sodium Phosphate 1.75)를 시료 건중량의 2%인 4kg을 투입하여 pH를 미리 5.5로 하여 버퍼액을 조제한다. 조제된 버퍼액을 미역시료에 첨가하고 10분 교반하여 미역 내 이온들과 혼합하여 완충능을 안정화 시키고, 온도를 60도씨 이하로 냉각한다.Water washing and primary desalted seaweed samples are added to a 5 ton fermentation tank, and 3 tons of purified water (15 times weight W / W of sample) warmed to 80 ° C in advance prior to the addition of Citrate-Phoshate buffer (mixture ratio Citrate 1: Sodium) Phosphate 1.75) is prepared by adding 4 kg of 2% of the dry weight of the sample to pH 5.5 beforehand to prepare a buffer solution. The prepared buffer solution is added to the seaweed sample and stirred for 10 minutes to mix with the ions in the seaweed to stabilize the buffer capacity and to cool the temperature below 60 ° C.
이후 시료 건물줄량의 2.0 % 인 다당분해효소를 투입하여 57℃에서 7시간 분해 한다. 이때 다당분해효소로서는 아스퍼질러스오리자 및 트리코더마리사이 기원의 복합 당질 분해효소(10,000 CU/g)로서 그 조성비가 1: 0.5 ~1 : 0.7% 인 것으로 에스티바이오스(주)의 에스씨원 등을 사용할 수 있다. 여기에 효소는 상기 제조사의 품목에 국한된 것은 아니다. Cellulose Unit로서 10,000 unit/g의 역가의 효소를 상기 시료 중량부의 W/W로 첨가하여 사용할 수 있다. Thereafter, polysaccharide dehydrogenase, which is 2.0% of the sample building amount, is added and decomposed at 57 ° C for 7 hours. At this time, the polysaccharide degrading enzyme is a complex glycolytic enzyme (10,000 CU / g) originated from Aspergillus orija and Trichodermari mari, and its composition ratio is 1: 0.5-1: 0.7%. Can be used. Enzymes are not limited to the items of the manufacturer. As a cellulose unit, an enzyme having a titer of 10,000 unit / g may be added to W / W of the sample weight part.
당질 효소분해 후 단백질성분을 추출하여 막여과로 제거하기 위해 프로테아제로서 복합효소인 태평양화학의 Protease NP를 미역 건물 중량부의 1%(W/W) 첨가하여 동일한 조건에서 4시간 분해한다. 여기에 사용되는 프로테아제는 상기 사의 효소에 국한된 것이 아니고, 바실러스 속 균주유래의 프로테아제를 사용할 수 있다. 효소분해 종료 후 121℃ 1 ~ 3시간 1.2kgf/cm2 의 압력 조건에서 가압하여 점도와 분자량을 조절한다. 평균분자량을 300,000 이하, 최종점도 15cP 로 조절하여 미역 효소분해액으로 하였다. 분해액을 초원심분리기(도모에공업, 일본)로 10,000 x g에서 연속 원심 분리하고, 스파킬러 필터( 10마이크로, 1마이크로, 0.22마이크로)로 3단계 여과한 후 여과액을 획득 하였다. 고형분 함량 5.7%의 2.9톤을 획득하였다. In order to extract protein components after carbohydrate digestion and remove them by membrane filtration, 1% (W / W) of Pacific Seaweed Protease NP, a complex enzyme as protease, is added and digested for 4 hours under the same conditions. The protease used herein is not limited to the enzyme of the above company, it is possible to use protease derived from the strain of the genus Bacillus. After completion of the enzymatic digestion, the mixture was pressurized under pressure conditions of 1.2 kgf / cm 2 at 121 ° C. for 1 to 3 hours to adjust the viscosity and molecular weight. The average molecular weight was 300,000 or less and the final viscosity was adjusted to 15 cP to prepare a wakame enzyme digestion liquid. The digestion solution was continuously centrifuged at 10,000 xg with an ultracentrifuge (Tomoe Industries, Japan), filtered three times with a spark killer filter (10 micro, 1 micro, 0.22 micro) to obtain a filtrate. 2.9 tons of solid content of 5.7% was obtained.
실시예Example 2. 미역 2. Seaweed 효소분해액으로 부터From enzyme digestion 황산화Sulfate 다당의 분리. Separation of polysaccharides.
황산기를 함유한 여러 올리고당, 즉 황산화 푸칸, 황산화 갈락탄, 황산화 푸코갈락탄 등은 갈조류의 알긴산이나 홍조류의 카라기난 등에서 식이섬유와 결합되어 항 혈액응고, 혈압강하, 항종양활성을 지니는 것으로 알려져 있고, 그 생리활성에 대한 연구가 최근 일본, 러시아 등지에서 활발히 진행되고 있다. Various oligosaccharides containing sulfate groups, such as sulfated fucan, sulfated galactan, sulfated fucogalactan, etc., are combined with dietary fiber in alginic acid of algae and carrageenan of red algae, and have anticoagulant, blood pressure lowering, and antitumor activity. It is known that research on its physiological activity has been actively conducted in Japan and Russia recently.
본 발명에서는 황산화 올리고당 류를 효소분해액으로 부터 획득하여 담즙산흡착능을 지니는 획분을 발명하여 제조공정이 간단하고, 수율이 높은 식품소재를 제공하고자 한다. In the present invention, by obtaining the sulfated oligosaccharides from the enzymatic digestion solution to invent a fraction having a bile acid adsorption capacity to provide a simple and high-yield food material.
미역 분해여과액 2.9톤을 각 수위별로 배출구가 옆으로 장착된 교반 탱크에 투입하고 염화칼슘을 총 중량의 8%인 23.2kg을 투입하여 15분간 65rpm으로 교반하면서 서서히 고분자 알긴산 응집물을 생성시키고, 이후 정치시켜 고분자 알긴산칼슘염을 침전시킨다. 수위관을 통해 침전 부위의 상청액을 배출하여 획득하였다. 이때 액량은 2.3톤이었다. 이를 0.01N HCl과 NaOH 로 재생한 Dion SA10AP(강염기성 음이온교환수지, 삼양사)를 이온교환수지탑(직경 30cm x 200cm)에 충진하여 상기 고분자 알긴산이 제거된 여액을 용출시켜 흡착한 후 2.0M 생리식염수로 재 용리 하여 탈착 수집하였다. 상기 수집액에 2배량의 정제수를 가하여 한외여과기(분자량 배제 5,000 달톤)를 사용하여 5회 탈염, 아미노산류 제거, 농축과정을 동시에 수반하고, 상기 농축액에 3배의 탈이온수를 가하여 희석한다. 이는 컬럼크로마토그래피 용출이 용이 하도록 하기 위하여 희석액을 첨가한다. 이때 농축액의 점도가 40cP 이상일 경우 15cP 이하가 되도록 탈이온수를 추가로 첨가할 수 있다. 상기 희석된 시료액을 25mM Tris-HCl(pH 7.0)과 1:1(v/v)의 용리액을 사용하여 Toyopearl HW- 65s를 충진한 Moduline Purificatin system(직경 14cm x 높이 160cm, 밀리포어사)를 50ml 씩 용출하여 분획하였다. 이 분획을 fucose를 표준품으로 하여 페놀황산법으로 전당함량을 측정한 피크의 유형에 따라 합하고 이를 동결건조 하여 미역 황산화 다당시료로 하였다. 상기 시료에서 2개의 획분을 획득하였으며 이를 UNDARIA SULFHATED FRACTION 을 줄여 USF로 하고, 각각 을 USF-1 획분(평균분자량 12만), USF-2획분(평균분자량 4만)라 하였다. 2.9 tons of seaweed digestion filtrate was added to a stirring tank equipped with a side outlet for each level, and 23.2 kg of calcium chloride was added at 8% of the total weight, and the mixture was stirred at 65 rpm for 15 minutes to gradually produce a polymer alginate aggregate. To precipitate the polymer calcium alginate salt. Obtained by draining the supernatant of the precipitation site through the water pipe. The liquid amount was 2.3 tons at this time. Dion SA10AP (strong base anion exchange resin, Samyangsa), which was regenerated with 0.01 N HCl and NaOH, was charged into an ion exchange resin tower (30 cm x 200 cm in diameter), and the filtrate from which the polymer alginic acid was removed was adsorbed. Re-elution with saline was collected by desorption. Two times the amount of purified water was added to the collection solution, followed by simultaneous desalination, amino acid removal and concentration using an ultrafilter (excluding 5,000 Daltons of molecular weight), followed by dilution of 3 times of deionized water. It is added with diluent to facilitate column chromatography elution. In this case, when the viscosity of the concentrate is 40 cP or more, deionized water may be further added so as to be 15 cP or less. The diluted sample solution was prepared using a Moduline Purificatin system (14 cm in diameter x 160 cm in height, Millipore Inc.) filled with Toyopearl HW-65s using 25 mM Tris-HCl (pH 7.0) and 1: 1 (v / v) eluent. Elution was performed by 50 ml. These fractions were combined according to the type of peaks measured by the phenol sulfate method using fucose as a standard, and lyophilized to obtain a seaweed sulfated polysaccharide sample. Two fractions were obtained from the sample, and the UNDARIA SULFHATED FRACTION was reduced to USF, and each was referred to as USF-1 fraction (average molecular weight 120,000) and USF-2 fraction (average molecular weight 40,000).
각 분획물의 황산화다당 황산화도를 측정하기 위하여 하기 실험을 행하였다.The following experiment was conducted to measure the degree of sulfated polysaccharide sulfate of each fraction.
일반성분은 식품공전 시험법에 준하여 실험하였고, 전당함량은 실품공전법의 페놀-황산법으로 시험하였으되 이때 표준품은 푸코스로 하였다. 구성당 조성분석은 HPLC를 이용하여 각기 단당 시료를 표준품으로 구한 검량선을 기초로 하여 분석하였다. General ingredients were tested according to the Food Code, and the content of sugar content was tested by the phenol-sulfuric acid method of Real Code, but the standard product was Fucos. Composition analysis was performed on the basis of calibration curves obtained by using HPLC as a standard.
상기 결과로 미루어 보아 효소분해 시 1차 효소분해 후 2차 단백질 효소분해를 통한 공정과 고분자 알긴산제거 공정시 흡착되어 침전제거된 단백질 량과 한외여과를 통해 제거된 양이 미역 건물중량의 20% 이상을 차지하는 것으로 나타났다. As a result, the amount of protein adsorbed and removed by ultrafiltration and the amount removed by ultrafiltration at 20% or more of seaweed dry weight during the enzymatic digestion process after the first enzymatic digestion and the second protein enzymatic digestion and the polymer alginate removal process. Accounted for.
해조 다당에서 중 황산기 함량은 그 기능적인 면에서 최근 새로운 개발분야로 자리 잡고 있다. 실제로 카라기난 등의 수출시장에서도 황산기 함량이 높은 것이 판매가도 높다. 또한 황산기를 포함하는 다당은 최소 25%이상을 함유하여야 일본 등의 수출시장에서 제품자격을 획득할 수 있다.The content of heavy sulfate groups in seaweed polysaccharides has recently become a new field of development. Indeed, even in export markets such as carrageenan, those with high sulfuric acid content also sell high. In addition, polysaccharides containing sulfate groups must contain at least 25% in order to obtain product qualification in export markets such as Japan.
따라서 본 발명의 획분의 황산기와 구성당 조성으로 황산기 함유도를 측정하였다.Therefore, the sulfuric acid group content was measured by the composition of the sulfuric acid group and constituent sugar of the fraction of this invention.
상기의 결과에서 우론산 함량은 알긴산의 기본구조로서 함량이 적을수록 점도가 감소하고, 알긴산을 제외한 다당류의 순도를 나타내는 척도가 된다. 또한 구성당의 조성은 각 구성당 피크를 총 100으로 할때 각 성분의 조성비를 나타낸 것이다. 푸코스 함량이 높고 다음으로 갈락토스 함량이 높았다. 특히 황산기 함량이 25%이상으로 나타났다. 즉, 이상의 결과에서 각각의 획분은 25%이상의 황산기를 함유하는 황산화 다당으로 나타났다. In the above results, uronic acid content is a basic structure of alginic acid, the smaller the content, the lower the viscosity, and a measure of purity of polysaccharides except alginic acid. In addition, the composition of constituent sugar shows the composition ratio of each component when the peak per each component totals 100. It was high in fucose and next in galactose. In particular, the sulfuric acid content is more than 25%. That is, in the above results, each fraction represented sulfated polysaccharide containing 25% or more sulfate groups.
실시예Example 3 3 담즙산Bile acid 흡착능Adsorption capacity 시험 exam
담즙산염의 준비 : Sodium cholate, sodium chenodeoxycholate, sodium deoxycholate는 Wako pure chemical Inc.(오사카, 일본)에서 구입하여 사용하였다. Preparation of bile salts: Sodium cholate, sodium chenodeoxycholate, sodium Deoxycholate was purchased from Wako pure chemical Inc. (Osaka, Japan).
담즙산염의 정량 : Chan, H j 등의 방법(korean J. Food Sci, Technol, 56, 348(1994) 을 사용하여 측정하였다. 담즙산용액(0.1% sodium azide 를 포함하는 0.1M 인산완충용액 pH7.0에 각각의 담즙산을 1-15mM 함유)0.5ml에 45%황산 3ml과 0.3% furfural 수용액 0.5ml를 넣고 65℃ 에서 30분간 반응시킨 후 나온 청색을 spectrophotometer로 680nm 에서의 흡광도를 측정하여 분석하였다.Quantification of bile salts was determined using the method of Chan, H j, et al. (Korean J. Food Sci, Technol, 56, 348 (1994), bile acid solution 0.1M phosphate buffer solution containing 0.1% sodium azide pH7.0 Each bile acid contained 1-15 mM) 0.5 ml of 45% sulfuric acid and 0.5 ml of 0.3% furfural solution were added and reacted at 65 ° C. for 30 minutes, and then the absorbance at 680 nm was measured using a spectrophotometer.
담즙산과 시료의 흡착시험 : Suzuki T 등의 방법(Fisheries Sci. 1996; 62: 454-461)에 따라 측정하였다. 각 획분 200mg에 2.5mM 의 각각의 담즙산염을 20ml를 원심관에 투입하고 37℃ 2시간 반응하여 13,000 x g 에서 10분간 반응하고 여과하고 여과액 중 담즘산염 량을 측정하였다. 각 획분 대신 증류수를 가하여 대조구로하고 담즙산량 흡착량은 실험구에서 대조구를 감산하여 산출하였다. Adsorption test of bile acids and samples: Measured according to the method of Suzuki T et al. (Fisheries Sci. 1996; 62: 454-461). 20 ml of each bile salt of 2.5 mM in each fraction was added to a centrifuge tube, reacted for 2 hours at 37 ° C. for 10 minutes at 13,000 × g, filtered, and the amount of bile salt in the filtrate was measured. Distilled water was added instead of each fraction as a control, and the amount of bile acid adsorption was calculated by subtracting the control from the experiment.
각 실험에 대하여 담즙산염 흡착능을 지닌 상업용 제제인 cholestyramine 을 대조구로 하여 비교 실험을 행하였다. For each experiment, a comparative experiment was conducted using cholestyramine, a commercial preparation with bile salt adsorption capacity.
도 1 - 도 3은 각 획분과 cholate, chenodeoxycholate, deoxycholate 와의 흡착을 배양시간을 140분 까지 유지하면서 실험한 결과 이다. 모두의 경우에서 담즙산과의 흡착시작점부터 흡착능이 발현되어 140분까지 유지되었다. 그러나 시간이 경과됨에 따라 특이한 경감은 없는 것으로 나타나 초기에 흡착이 완결되는 것으로 나타났다. 흡착에 대한 농도를 umol/g 으로 나타내었다. 그 결과 1차담즙산염에 대한 흡착능은 미비하였으나 2차담즙산염에 대한 흡착능이 약용으로 상용되는 cholestyramine 보다는 효과가 약하였으나 식품소재로서의 획분으로서 그 효과가 뛰어나다고 할 수 있다. 도 4.는 2차 담즙산염인 Sodium deoxycholate에 대한 USF-1 획분이 콜레스틸아민 다음으로 흡착능이 있음을 나타내는 그림으로서 그 흡착능을 대조구에 대하여 %로 나타내면 78%에 달한다. 따라서 분자량 12만의 USF-1 획분은 황산기를 28.7%를 함유하고 있으며 구성당비율 중 푸코스와 갈락토스 함량이 높은 황산화 다당으로 2차 담즙산염 흡착능이 우수한 획분이었다.1 to 3 show the results of experiments with adsorption of each fraction with cholate, chenodeoxycholate and deoxycholate while maintaining the incubation time up to 140 minutes. In all cases, adsorption capacity was expressed from the starting point of adsorption with bile acid and maintained for 140 minutes. However, over time, there was no specific alleviation, indicating that the adsorption was initially completed. The concentration for adsorption is expressed in umol / g. As a result, the adsorption capacity for primary bile salts was inadequate, but the adsorption capacity for secondary bile salts was less effective than cholestyramine, which is commonly used for medicinal purposes. 4 is a diagram showing that the USF-1 fraction of the second bile salt, sodium deoxycholate, has the adsorption capacity after the cholestylamine, and the adsorption capacity reaches 78% of the control. Therefore, USF-1 fraction of 120,000 molecular weight contains 28.7% of sulfate group, and it is a fraction of sulfated polysaccharide with high content of fucose and galactose in constituent sugar ratio.
대규모 생산자원인 미역을 이용하여 새로운 공정법에 의해 2차 담즙산염이 Deoxycholate 흡착능이 있는 획분을 분리하였다. 식품소재로서 황산화다당 및 올리고머인 이 획분은 콜레스테롤 과다 섭취로 인한 내인성 콜레스테롤 축적 예방에 관여하는 식품소재로서 산업화가 가능하다. 또한 미역을 효소로 분해하여 그 고형분 수율을 증대 시키므로서 2차 공정에서 고분자 알긴산을 제거하므로써 낮아지는 수유을 초기에 극복할 수 있다. 본 발명은 미역을 이용하여 2차담즙산을 흡착하여 배출시키고, 부족분의 담즙산을 생성하기 위해 생체내 콜레스테롤을 재이용하게 하는 Feed back 효과를 야기하는 황산화다당 획분에 관한 것으로서 미역의 고기능성 이용으로 그 이용율이 확대되고, 단순가공을 탈피하여 어민의 소득보장에도 기여하며, 황산화다당의 수요가 많은 일본, 유럽시장에서 성장을 기대할 수 있는 식품소재로서의 역할을 담보할 것으로 사료된다.Secondary bile salts were fractionated with deoxycholate adsorption capacity by a new process using seaweed, a large-scale production resource. This fraction, which is a sulfated polysaccharide and oligomer as a food material, can be industrialized as a food material involved in preventing endogenous cholesterol accumulation due to excessive cholesterol intake. In addition, it is possible to overcome lactation lowered by removing the polymer alginic acid in the secondary process by increasing the solids yield by decomposing seaweed into enzymes. The present invention relates to a sulfated polysaccharide fraction which causes a feed back effect of adsorbing and releasing secondary bile acids by using seaweed and reusing cholesterol in vivo to produce a deficiency of bile acids. It is expected to contribute to securing income for fishermen by expanding the utilization rate, avoiding simple processing, and securing a role as a food material that can be expected to grow in the Japanese and European markets where demand for sulfated polysaccharide is high.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050123015A KR20070063112A (en) | 2005-12-14 | 2005-12-14 | Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050123015A KR20070063112A (en) | 2005-12-14 | 2005-12-14 | Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070063112A true KR20070063112A (en) | 2007-06-19 |
Family
ID=38363200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050123015A Abandoned KR20070063112A (en) | 2005-12-14 | 2005-12-14 | Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20070063112A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018070609A (en) * | 2016-10-24 | 2018-05-10 | 奥野製薬工業株式会社 | Bile acid absorbent and adiponectin secretion enhancer |
-
2005
- 2005-12-14 KR KR1020050123015A patent/KR20070063112A/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018070609A (en) * | 2016-10-24 | 2018-05-10 | 奥野製薬工業株式会社 | Bile acid absorbent and adiponectin secretion enhancer |
| JP2022031537A (en) * | 2016-10-24 | 2022-02-18 | 奥野製薬工業株式会社 | Adiponectin secretion promoting agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102080562B1 (en) | Hypoglycemic hyper-branched maltodextrins | |
| CN111285939B (en) | Artemisia annua polysaccharide with effects of resisting oxidation and regulating intestinal flora and preparation method and application thereof | |
| CN111019008B (en) | A kind of anti-inflammatory active Phellinus linteus polysaccharide SHP and preparation method thereof | |
| EP2989156A1 (en) | Phytoglycogen nanoparticles and methods of manufacture thereof | |
| CN108359026B (en) | Preparation method and application of water-insoluble xylan | |
| CN1362860A (en) | Low-molecular weight polymannuronate | |
| JP4420470B2 (en) | Abalone polysaccharide extraction method | |
| US20170369597A1 (en) | Phytoglycogen nanoparticles and methods of manufacture thereof using corn | |
| CN115028750B (en) | Ascophyllum nodosum fucoidan and its preparation method and application | |
| CN115595351A (en) | A kind of foie gras protein peptide and its preparation method and application | |
| JP3043888B2 (en) | Colorectal cancer prophylactic agent containing glucomannan partial hydrolyzate as active ingredient | |
| CN107216405A (en) | The preparation technology and its structure sequence of a kind of highland barley beta glucan | |
| CN112691115A (en) | Arabinoxylan and compound for preventing/treating gastrointestinal mucosa and liver injury | |
| KR20160149748A (en) | Method for producing higher-pyrity and depolymerizing fucoidan extracted from brown algae | |
| CN115010825A (en) | A kind of preparation method of zucchini pectin rich in RG-I structure | |
| CN111280453B (en) | A kind of preparation method of Antrodia camphorata water-insoluble dietary fiber | |
| KR20070063112A (en) | Sulfated Polysaccharide Fraction Having Secondary Bile Adsorption Capacity and Its Manufacturing Method | |
| CN106749733A (en) | A kind of yellow tang controlling sulfate polyose and preparation method thereof, application | |
| CN116965500A (en) | A solid drink with health-care functions | |
| Atallah et al. | Effect of pectin structure on protein utilization by growing rats | |
| CN116333187A (en) | Preparation and application of 100% methylated pectin in banana pulp | |
| JPH03209331A (en) | Substance for improving intestinal environment | |
| JP7312485B2 (en) | adiponectin secretagogue | |
| JP4222012B2 (en) | Antihyperlipidemic agent | |
| CN116254308B (en) | Preparation method of red cardamom skeleton polysaccharide and its products and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20051214 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20101210 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20051214 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120824 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20130620 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20131231 |
|
| PC1904 | Unpaid initial registration fee |